Akeso Advances Oncology Pipeline with EGFR/TROP2 Bispecific ADC Clearance

The approval marks a milestone for the Hong Kong-based biopharmaceutical firm, establishing AK158D1 as its fourth clinical-stage ADC and its second bispecific candidate in this class. By simultaneously engaging two validated tumor targets, the drug aims to provide broader tumor coverage and mitigate the multidrug resistance often observed in current standard-of-care treatments.

Preclinical assessments have indicated that the dual-targeting mechanism yields potent anti-tumor activity while maintaining a favorable safety profile. The company intends to position this candidate for patients who are refractory or ineligible for existing therapeutic regimens. This development aligns with Akeso’s broader IO2.0 and ADC2.0 strategy, which integrates proprietary multi-specific antibody technology with cytotoxic payloads to address the narrow therapeutic windows of first-generation ADCs. The clinical trial will evaluate the drug's safety and efficacy in patients diagnosed with advanced malignant solid tumors.